Direct Evidence of Acetaminophen Interference with Subcutaneous Glucose Sensing in Humans: A Pilot Study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent advances in accuracy and reliability of continuous glucose monitoring (CGM) devices have focused renewed interest on the use of such technology for therapeutic dosing of insulin without the need for independent confirmatory blood glucose meter measurements. An important issue that remains is the susceptibility of CGM devices to erroneous readings in the presence of common pharmacologic interferences. We report on a new method of assessing CGM sensor error to pharmacologic interferences using the example of oral administration of acetaminophen. MATERIALS AND METHODS: We examined the responses of several different Food and Drug Administration-approved and commercially available CGM systems (Dexcom [San Diego, CA] Seven(®) Plus™, Medtronic Diabetes [Northridge, CA] Guardian(®), and Dexcom G4(®) Platinum) to oral acetaminophen in 10 healthy volunteers without diabetes. Microdialysis catheters were placed in the abdominal subcutaneous tissue. Blood and microdialysate samples were collected periodically and analyzed for glucose and acetaminophen concentrations before and after oral ingestion of 1 g of acetaminophen. We compared the response of CGM sensors with the measured acetaminophen concentrations in the blood and interstitial fluid. RESULTS: Although plasma glucose concentrations remained constant at approximately 90 mg/dL (approximately 5 mM) throughout the study, CGM glucose measurements varied between approximately 85 to 400 mg/dL (from approximately 5 to 22 mM) due to interference from the acetaminophen. The temporal profile of CGM interference followed acetaminophen concentrations measured in interstitial fluid (ISF). CONCLUSIONS: This is the first direct measurement of ISF concentrations of putative CGM interferences with simultaneous measurements of CGM performance in the presence of the interferences. The observed interference with glucose measurements in the tested CGM devices coincided temporally with appearance of acetaminophen in the ISF. The method applied here can be used to determine the susceptibility of current and future CGM systems to interference from acetaminophen or other exogenous pharmacologic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The artificial pancreas: current status and future prospects in the management of diabetes
Peyser, T., Dassau, E., Breton, M., & Skyler, J. S. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12431 · Cited by 169
Self-citationClinical accuracy of a continuous glucose monitoring system with an advanced algorithm
Bailey, T. S., Chang, A., & Christiansen, M. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814559746 · Cited by 168 · cited 1×
“A survey of participants in the T1D Exchange clinic registry in 2014 found that almost 10% of patients used a CGM device during a 30-day period.(4) A recent in silico study by Kovatchev et al.”
Cited by
Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
Drucker, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa011 · Cited by 399
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
El-Khatib, F. H., Balliro, C., Hillard, M. A., Magyar, K. L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32567-3 · Cited by 254
Xie, X., Doloff, J. C., Yesilyurt, V., Sadraei, A., McGarrigle, J. J., Omami, M., Veiseh, O., Farah, S., Isa, D., Ghani, S., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0273-3 · Cited by 235
Galindo, R. J., Aleppo, G., Klonoff, D. C., Spanakis, E. K., Agarwal, S., Vellanki, P., Olson, D. E., Umpierrez, G. E., Davis, G. M., & Pasquel, F. J. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820932903 · Cited by 155
“21,23 In the latest version (G6), the addition of a permselective membrane coating to the sensor surface inhibits the diffusion of molecules that can generate potentially spurious signals into the sensor, eliminating the risk of acetaminophen interference at therapeutic doses (up to 1000 mg every…”
Lorenz, C., Sandoval, W., & Mortellaro, M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0028 · Cited by 80
“Indeed, Basu et al. 39 reported for the Dexcom Seven Plus, Medtronic Diabetes Guardian, and Dexcom G4 Platinum CGM systems that a single 1-g dose of acetaminophen in participants who had plasma glucose levels of 90 mg/dL had sensor measurements that varied over a wide range (85–400 mg/dL).”
Laffel, L. M., Aleppo, G., Buckingham, B. A., Forlenza, G. P., Rasbach, L. E., Tsalikian, E., Weinzimer, S. A., & Harris, D. R. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00389 · Cited by 79
“Importantly, patients should be cautioned about use of medications that contain acetaminophen, which can cause the rtCGM system to display false high readings for up to and beyond 6 hours following ingestion [34, 35]. the 1500 and 1960 rules to infer correction doses [36].”
BackgroundContinuous Glucose Monitor Interference With Commonly Prescribed Medications: A Pilot Study
Basu, A., Slama, M. Q., Nicholson, W. T., Langman, L., Peyser, T., Carter, R., & Basu, R. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817697329 · Cited by 77
Self-citationInterferences with CGM systems: practical relevance?
Heinemann, L. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211065065 · Cited by 65
Polsky, S., Buschur, E., Dungan, K., Garcetti, R., Nease, E., Malecha, E., Bartholomew, A., Johnson, C., Pyle, L., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0012 · Cited by 39
Benefits and limitations of continuous glucose monitoring in type 1 diabetes
Stone, J. Y., & Bailey, T. S. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1706482 · Cited by 30
Denham, D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820948544 · Cited by 28
“518 Journal of Diabetes Science and Technology 15(2)”
Pfützner, A., Jensch, H., Cardinal, C., Srikanthamoorthy, G., Riehn, E., & Thomé, N. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221095573 · Cited by 20
“10 At the same time, the manufacturers tried to solve known interference issues and in 2018, Calhoun and coworkers reported a next generation CGM device (G6), where acet-aminophen interference appeared to be solved by use of a novel permselective membrane coating for the needle sensor.”
BackgroundSchiavon, M., Acciaroli, G., Vettoretti, M., Giaretta, A., & Visentin, R. (2018) · 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2018.8512257 · Cited by 5
“, the common orally administered acetaminophen (APAP) which artificially raises CGM readings for several hours [6][7].”
Influential
Metadata
- Authors
- Basu, A., Veettil, S., Dyer, R., Peyser, T., & Basu, R.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2016-02
- Volume
- 18
- Issue
- S2
- Pages
- S2-43-S2-47
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2430544025
- Cited by
- 93
- References
- 2
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.